PAUL FICKES: Open Payments
NPI 1710487897 · MEDFORD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$419 in 19 payments from 13 companies in 2025. Trend: 2023 $701 · 2024 $392 · 2025 $419
Food & beverage: $419
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
Products named: SPRAVATO, CAPLYTA, AUSTEDO XR, REXULTI, FANAPT, VRAYLAR, Auvelity, COBENFY.
Industry payments across OR — which companies pay providers there.
